Evotec and Active Biotech Enter into Medicinal Chemistry Collaboration

6/6/2011, 7:31 AM (Source: GlobeNewswire)
Evotec AG /
Evotec and Active Biotech Enter into Medicinal Chemistry Collaboration
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

Hamburg, Germany - 6 June 2011: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) today announced that it has entered into a medicinal chemistry
collaboration with Active Biotech AB (NASDAQ OMX: ACTI), following the
successful conclusion of a High Throughput Screening campaign to identify small
molecule modulators of a priority biological target, selected by Active Biotech,
involved in immune disorders and cancer.

Based on excellent progress made using its state-of-the-art Screening Platform
in 2010, Evotec will now apply its integrated medicinal chemistry platform to
optimise initial screening hits with the aim of progressing into a lead
optimisation programme.

Dr Mario Polywka, Chief Operating Officer at Evotec stated: "We are delighted
that our screening collaboration with Active Biotech has identified quality hits
that we can now progress into a lead identification programme. This
collaboration is a validation of our hit finding platform and also the
confidence Active Biotech have in Evotec to support the further progress of this
project. We look forward to working with the team at Active Biotech in their
quest to find novel treatments to address immune disorders and cancer."

Dorthe da Graça Thrige, Director of Development of Active Biotech, commented:
Active Biotech strives to develop, efficiently and cost-effectively, new
remedies for illnesses where today's treatment options are inadequate,
especially in the area of cancer and autoimmune diseases.  It is key for us to
collaborate with first class companies and we have been very impressed with
Evotec's hit identification activities on this important target and now look
forward to progressing the hits through hit to lead."

No financial details are disclosed.

Contact Evotec AG: Dr Werner Lanthaler, Chief Executive Officer, Phone:
+49.(0)40.56081-242, werner.lanthaler@evotec.com

Active Biotech AB
Dorthe da Graça Thrige, PhD
Director, Development
Scheelevägen 22
PO Box 724
SE-220 07 Lund
+46 (0)46.19 20 00
+46 (0)46.19 11 00 Fax

Forward-Looking Statements - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety of
risks and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or undertaking
to release publicly any updates or revisions to any such statements to reflect
any change in our expectations or any change in events, conditions or
circumstances on which any such statement is based.

--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

PDF of Press release:

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Evotec AG via Thomson Reuters ONE

Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.